在可治愈病因的肝硬化患者中验证并扩展Baveno VII再代偿标准
本研究在525例可治愈病因(酒精、HCV、HBV)的失代偿期肝硬化门诊患者中验证Baveno VII再代偿标准,298例接受有效病因治疗者中21例(7%)达到再代偿,112例(37.6%)达到扩展再代偿标准。再代偿与代偿期患者死亡风险无显著差异(HR 0.97;p=0.947),失代偿患者死亡风险最高(HR 4.96;p<0.001),扩展标准与Baveno VII标准者死亡风险无显著差异(HR 0.97;p=0.938)。
要点
- Baveno VII再代偿标准可识别预后良好的肝硬化患者,但仅7%失代偿患者达到。
- 扩展再代偿标准(低剂量利尿剂和/或乳果糖/利福昔明≥12个月)可识别死亡风险同样低的患者。
- 再代偿与代偿期患者死亡风险无显著差异,失代偿患者死亡风险最高。
核心结论
- Baveno VII标准可识别预后良好的肝硬化患者,但不足10%的失代偿患者达到再代偿。
- 将标准扩展至接受最小化失代偿治疗的患者,可识别死亡风险同样低的患者。
研究设计与样本
- 连续纳入可治愈病因(酒精、HCV、HBV)的肝硬化门诊患者并随访。
- 共525例失代偿期肝硬化门诊患者,其中298例接受有效病因治疗。
- 对160例患者检测血清炎症细胞因子(IL-6、IL-1β、IL-10)。
- 使用外部队列验证研究结果。
主要发现
- 298例接受有效病因治疗者中21例(7%)达到Baveno VII再代偿标准,112例(37.6%)达到扩展再代偿标准。
- MELD评分(sHR 0.89;p<0.001)、BMI(sHR 0.93;p=0.020)、血红蛋白(sHR 1.14;p=0.010)和进一步失代偿(sHR 0.50;p=0.001)是再代偿的独立预测因素。
- 再代偿患者与代偿期患者死亡风险无显著差异(HR 0.97;p=0.947),失代偿患者死亡风险最高(HR 4.96;p<0.001)。
- 达到扩展再代偿标准与Baveno VII标准者死亡风险无显著差异(HR 0.97;p=0.938)。
- 失代偿患者血清IL-6、IL-1β和IL-10显著高于代偿期和再代偿患者。
关键数值与推荐
- 再代偿定义依据Baveno VII标准。
- 扩展再代偿标准适用于使用低剂量利尿剂和/或乳果糖/利福昔明≥12个月的患者。
临床怎么用
- Baveno VII标准可用于识别预后良好的肝硬化患者。
- 扩展标准可将接受最小化失代偿治疗的患者纳入再代偿评估,其死亡风险与Baveno VII标准者相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The Baveno VII group recently proposed criteria to define recompensation in patients with decompensated cirrhosis achieving etiological cure. However, the incidence, predictors and clinical significance of recompensation are poorly understood. The aim of this study was to evaluate the incidence and prognostic impact of recompensation in patients with decompensated cirrhosis. METHODS: Outpatients with cirrhosis and curable etiologies (alcohol, HCV, HBV) were consecutively included and followed up. Recompensation was defined according to Baveno VII criteria. Additionally, expanded recompensation criteria were evaluated for patients on low-dose diuretics and/or lactulose/rifaximin for ≥12 months. In 160 patients, inflammatory cytokines (IL-6, IL-1β, IL-10) were measured in serum samples. An external cohort was used to validate study findings. RESULTS: Out of 525 outpatients with decompensated cirrhosis, 298 received effective etiological treatment and 21 (7%) achieved recompensation (Baveno VII criteria), while 112 patients achieved expanded recompensation criteria (37.6%). MELD score (subdistribution hazard ratio [sHR] 0.89; p <0.001), BMI (sHR 0.93; p = 0.020), hemoglobin (sHR 1.14; p = 0.010) and further decompensation (sHR 0.50; p = 0.001) were independent predictors of recompensation. In multivariable analysis, mortality risk was not significantly different between patients achieving recompensation and compensated patients (HR 0.97; p = 0.947), while decompensated patients had the highest mortality risk (HR 4.96; p <0.001). Mortality risk was not significantly different between patients meeting expanded recompensation criteria and Baveno VII criteria (HR 0.97; p = 0.938). Serum IL-6, IL-1β and IL-10 were significantly higher in decompensated patients than in compensated and recompensated patients. CONCLUSION: Baveno VII criteria identify patients with cirrhosis and a good prognosis, but fewer than 10% of decompensated patients achieve recompensation. Expanding these criteria to include patients receiving minimal decompensation treatment identifies those with similarly low mortality risk. IMPACT AND IMPLICATIONS: In recent years, growing evidence has shown that achieving an etiological cure can significantly improve the prognosis of patients with decompensated cirrhosis, leading to the concept of recompensation. The Baveno VII group recently proposed criteria to define recompensation; however, data on the clinical impact of this state remain limited. In this study we evaluated Baveno VII criteria and developed and validated expanded Baveno VII criteria for recompensation. Our findings demonstrate that recompensation is associated with improved survival, reduced hyperdynamic circulation and decreased systemic inflammation in outpatients with decompensated cirrhosis. These results are valuable for hepatologists and researchers aiming to refine patient management strategies and risk stratification in cirrhosis care.
引用
- Tonon M, Gagliardi R, Pompili E, et al. Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease. J Hepatol. 2025. PMID: 40228583. doi:10.1016/j.jhep.2025.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。